Baudax Bio Inc reports results for the quarter ended in September - Earnings Summary

Baudax Bio

08/11/2022 23:27

* Baudax Bio Inc  BXRX.OQ  reported a quarterly adjusted
loss
of 66 cents​​ per share for the quarter ended in September. The
lone analyst forecast for the quarter was for a loss of 53 cents
per share.
    * Revenue fell 15.3% to $238.00 thousand from a year ago;
analysts
expected $965.00 thousand. 
    * Baudax Bio Inc's reported EPS for the quarter was a loss
of
$2.47​.
    * The mean earnings estimate of analysts had risen by
about 32.1%
in the last three months.​ 
    * In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
    * Baudax Bio Inc shares had fallen by 24.4% this quarter and
lost 97.6% so far this year.
    * The company reported a quarterly loss of $29.21 million.
    * Wall Street's median 12-month price target for Baudax Bio
Inc is
$2.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 1 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 

This summary was machine generated from Refinitiv data November
8 at 11:27 p.m.  ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Sep. 30 2022      -0.53          -0.66          Missed
 Jun. 30 2022      -1.27          -0.06          Beat
 Mar. 31 2022      -1.85          -3.17          Missed
 Dec. 31 2021      1.48           10.03          Beat